Company FSD Pharma Inc.

Equities

HUGE

CA35954B4047

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sector Bio Therapeutic Drugs

Market Closed - Canadian Securities Exchange Other stock markets 03:59:19 2024-04-23 pm EDT			5-day change	1st Jan Change
0.64 ^CAD	0.00%		-7.25%	-46.67%

Apr. 08	FSD Pharma Receives Nasdaq Non-Compliance Notice	MT
Mar. 29	FSD Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

FSD Pharma Inc. is a Canada-based biotechnology company. The Company operates through two segments: Biotechnology and Strategic Investments. Its Biotechnology segment is focused on furthering the research and development of the Companyâs two primary drug candidates consisting of Lucid-MS and Lucid-PSYCH, as well as the development of UNBUZZD. The Companyâs Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial real estate property. Lucid-PSYCH is a molecular compound identified for the potential treatment of mental health disorders. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders. UNBUZZD is a proprietary formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of potentially quickly relieving from the effects of alcohol consumption, such as inebriation, and restoring normal lifestyle.

Number of employees: 17

Managers	Title	Age	Since
Zeeshan Saeed CEO	Chief Executive Officer	54	94-10-19
Anthony Durkacz FOU	Founder	47	94-10-19
Nathan Coyle DFI	Director of Finance/CFO	43	19-12-31
Andrzej Chruscinski CTO	Chief Tech/Sci/R&D Officer	-	-
Donal Carroll COO	Chief Operating Officer	48	18-06-30
Sandy Huard IRC	Investor Relations Contact	-	-
Patrick Oyanango PRN	Corporate Officer/Principal	-	21-12-31
Maryann Adesso HRO	Human Resources Officer	-	-

Members of the board	Title	Age	Since
Anthony Durkacz FOU	Founder	47	94-10-19
Donal Carroll COO	Chief Operating Officer	48	18-06-30
Lakshmi Kotra BRD	Director/Board Member	53	22-11-24
Zeeshan Saeed CEO	Chief Executive Officer	54	94-10-19
Eric Hoskins BRD	Director/Board Member	63	23-05-24
Adnan Bashir BRD	Director/Board Member	54	21-05-31
Michael Zapolin BRD	Director/Board Member	-	23-06-28

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	72	0	0	82.63 %
Stock B	1	40,429,569	33,407,248 ( 82.63 %)	0

Name	Equities	%	Valuation
Zeeshan Saeed 5.614 %	2,241,146	5.614 %	2 M $
Anthony Durkacz 3.749 %	1,496,836	3.749 %	1 M $
Lakshmi Kotra 3.562 %	1,422,197	3.562 %	1 M $
Donal Carroll 2.438 %	973,268	2.438 %	696 860 $
Raza Bokhari 1.581 %	631,086	1.581 %	451 858 $
AdvisorShares Investments LLC 0.6771 %	270,316	0.6771 %	193 546 $
Renaissance Technologies LLC 0.1733 %	69,200	0.1733 %	49 547 $
Scotia Capital, Inc. 0.1535 %	61,273	0.1535 %	43 871 $
UBS Securities LLC 0.0660 %	26,362	0.0660 %	18 875 $
Group One Trading LP 0.0442 %	17,653	0.0442 %	12 640 $

Name	Equities	%	Valuation
Fortius Research & Trading Corp. 0.2400 %	36	0.2400 %	37 $
Zeeshan Saeed 0.2400 %	36	0.2400 %	37 $
Raza Bokhari 0.1600 %	24	0.1600 %	25 $

FSD Pharma, Inc.

199 Bay Street Suite 4000

M5L 1A9, Toronto

+416 854 8884

http://www.fsdpharma.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
FSD PHARMA INC.	-46.67%	18.78M
VERTEX PHARMACEUTICALS INCORPORATED	-0.49%	105B
REGENERON PHARMACEUTICALS, INC.	+3.31%	97.5B
ARGENX SE	+3.29%	22.19B
BIONTECH SE	-16.16%	21.33B
GENMAB A/S	-7.80%	18.68B
WUXI APPTEC CO., LTD.	-41.41%	16.6B
BEIGENE, LTD.	-22.87%	14.52B
NEUROCRINE BIOSCIENCES, INC.	+6.32%	14.09B
SAREPTA THERAPEUTICS, INC.	+21.46%	10.99B

Bio Therapeutic Drugs